Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Name: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Published: 2017
License: Public Domain

Atara Biotherapeutics · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

autoimmune-disease autoimmunity cell-therapy central-nervous-system inflammation t-cell

primary progressive multiple sclerosis, secondary progressive multiple sclerosis, multiple sclerosis (ms), epstein-barr virus (ebv), ebv-associated multiple sclerosis, inflammation, central nervous system, autoimmune disease, autoimmunity, demyelination, cell therapy, t-cell

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 849820
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.